The American cancer society estimated there would be 21,980 new cases of ovarian cancer (OV) and 14,270 deaths in 2014 \[[@R1]\] with epithelial ovarian carcinoma accounting for approximately 90% of all cases \[[@R2]\], making ovarian cancer the most lethal gynecological cancer in the United States \[[@R3]\], and the fifth most deadly cancer in women. The 5-year survival rate is approximately 50% because early diagnosis is not usually possible as symptoms of this cancer are nonspecific and common testing methods are not likely to detect this disease in the early stages \[[@R4]\].

Recently there have been an emergence of large-scale -omics projects whose goal is to allow accurate and complete analysis of the mutational profile of disease, and the availability of this data has already yielded novel insights into the mutational spectrum of several cancers, including ovarian cancer \[[@R5], [@R6]\]. However, the analysis of genomic variation is not yet complete as there remains a largely overlooked source of variation at certain genomic regions such as microsatellites. Microsatellites are low complexity, repetitive DNA regions that have been associated with morphological changes and human diseases, notably with triplet repeat instability disorders \[[@R7]\], and have traditionally been thought of as having extremely high levels of polymorphism and heterozygosity, compared to high complexity DNA sequences \[[@R8]\]. However, our analysis of all available loci has shown that 98% of microsatellite loci are invariant, that is have less than a 1% polymorphism rate (manuscript in preparation). Microsatellites are ubiquitous and are over-represented in the human genome compared to expected levels that would be present by chance \[[@R9]\]. Their high frequency and relative invariance in disease-free populations make microsatellites good candidates to become informative markers for cancer and disease progression. Recently, algorithms specifically designed to accurately assess variation within microsatellites have been developed \[[@R10]--[@R13]\]. The growing availability of high-quality next-generation sequencing data, our accurate microsatellite genotyping algorithm and the ability to do genomics on a population scale have now combined to allow us to analyze microsatellite variation en masse. We have performed an analysis of microsatellites on a population level to (A) determine the normal range of variation, defined as variation found in individuals sequenced as part of the 1000 Genomes Project (1kGP), (B) use the genotype distribution at each microsatellite locus among healthy individuals as the baseline for comparison to genomes from individuals diagnosed with epithelial ovarian cancer from The Cancer Genome Atlas (TCGA) to assess the ability of greater OV-associated microsatellite variation as a potential novel risk assessment method and (C) use matching tumor and germline genotype distributions to identify "hot spots" for acquired variation in tumors as a potential personal genomics tool.

RESULTS {#s1}
=======

Establishing the normal range of microsatellite variation from the 1kGP {#s1_1}
-----------------------------------------------------------------------

In order to evaluate microsatellite instability in cancer patient data from TCGA, we first needed to establish a baseline for variation within the healthy population at each microsatellite locus. To do this we analyzed variation at each microsatellite locus in 249 females of European ancestry from the 1kGP data set ethnically matched to the OV cancer population of The Cancer Genome Atlas (TCGA). As our control set was from the 1,000 genomes project, no medical or phenotype information was provided for these individuals. At the time of sequencing, this population consisted of people who had not been diagnosed with cancer, therefore it should not be enriched for cancer-associated variants; however, given that a woman\'s lifetime risk of developing ovarian cancer is 1:72, we would expect that approximately 3 individuals in the healthy cohort will develop OV.

For comparisons to the OV data set, data from 249 females of European ancestry sequenced by the 1kGP was used to determine baseline variation. This control population was originally used for a similar study to identify a set of microsatellites that could distinguish Breast Cancer germline samples from the healthy population \[[@R14]\]. The same control group is used in this study to allow comparisons between the two signature microsatellite sets.

Microsatellite variation in OV {#s1_2}
------------------------------

Next-generation sequencing data from 305 germline samples from females diagnosed with OV, were obtained from TCGA \[[@R15]\]. The genotype at all microsatellite loci with at least 15X read depth coverage was determined. We then identified the most common genotype present within the healthy population and designated it as the 'modal' genotype. All other genotypes are then considered non-modal. For each population then we determined the frequency of modal and non-modal genotypes at each locus. Comparison of this frequency between the healthy and OV populations led to identification of 60 statistically significant microsatellite loci (Table [1](#T1){ref-type="table"}) that passed stringent Type 1 and False Discovery tests (*p* \< 0.001 by Fisher\'s exact test and adjusted *p* \< 0.01 by Benjamani Hochberg).

###### Statistically significant loci that differentiate healthy from OV cancer germlines

Loci demarked in bold were also informative for breast cancer using a similar approach. Encode and other element designations (from the UCSC browser) are as follows: 1 -- Transcription factor binding site, 2 -- DNaseI hypersensitivity locus, 3 -- Spliced EST, 4 -- H3K27Ac mark (found near active regulator elements), 5 -- human mRNA.

  Microsatellite Locus             Motif         Region       Gene          Encode element / other   1kGP samples genotyped   Percent 1kGP Non-modal   OV Samples Genotyped   Percent OV Non-modal   Relative Risk
  -------------------------------- ------------- ------------ ------------- ------------------------ ------------------------ ------------------------ ---------------------- ---------------------- ---------------
  chr5:122714135--122714152        A             intron       CEP120                                 50                       10%                      70                     64%                    6.4
  chr2:91886031--91886042          A             intergenic   --                                     186                      14%                      240                    48%                    3.4
  **chr5:133944044--133944059**    **T**         **intron**   **SAR1B**                              **17**                   **29%**                  **13**                 **100%**               **3.4**
  chr5:158511580--158511594        A             intron       EBF1          1                        33                       24%                      38                     82%                    3.4
  chr10:69699479--69699497         AT            intron       HERC4                                  79                       14%                      120                    39%                    2.8
  chr2:223339530--223339550        T             intron       SGPP2                                  22                       36%                      41                     85%                    2.3
  chr7:81695843--81695858          A             intron       CACNA2D1                               42                       38%                      83                     87%                    2.3
  chr18:21120382--21120397         A             intron       NPC1          1, 2                     42                       43%                      60                     93%                    2.2
  chr13:49951024--49951057         ATAG          intron       CAB39L                                 140                      26%                      217                    52%                    2.0
  chr2:234368716--234368729        A             intron       DGKD                                   20                       50%                      114                    93%                    1.9
  chr11:30438959--30438973         T             intron       MPPED2                                 40                       53%                      87                     14%                    1.8
  chr12:75901962--75901976         A             intron       KRR1                                   41                       51%                      94                     12%                    1.8
  **chr9:5798652--5798666**        **A**         **intron**   **ERMP1**                              **22**                   **45%**                  **91**                 **2%**                 **1.8**
  **chr19:30106131--30106147**     **T**         **intron**   **POP4**                               **30**                   **53%**                  **41**                 **95%**                **1.8**
  chr14:91928846--91928860         T             intron       SMEK1         2                        28                       54%                      42                     95%                    1.8
  chr1:149900986--149901001        A             exon         MTMR11        2, 3, 5                  37                       51%                      54                     89%                    1.7
  chr9:52626--52640                A             intergenic   \-                                     44                       55%                      90                     92%                    1.7
  **chr3:98299708--98299720**      **A**         **intron**   **CPOX**                               **56**                   **46%**                  **42**                 **10%**                **1.7**
  chr20:44333327--44333340         T             intron       WFDC10B                                80                       45%                      90                     76%                    1.7
  chr4:186188374--186188387        A             intron       SNX25                                  75                       47%                      127                    12%                    1.7
  **chr11:62565909--62565944**     **AA AAGA**   **intron**   **NXF1**                               **37**                   **38%**                  **90**                 **0%**                 **1.6**
  chr11:116691512--116691528       ACAG          exon         APOA4         5                        156                      53%                      222                    84%                    1.6
  **chr11:110128926--110128940**   **A**         **intron**   **RDX**       **3**                    **42**                   **40%**                  **78**                 **5%**                 **1.6**
  **chr17:63747018--63747031**     **A**         **intron**   **CEP112**    **1, 2, 3**              **48**                   **40%**                  **118**                **6%**                 **1.6**
  chr9:133498230--133498244        A             intron       FUBP3                                  37                       41%                      83                     8%                     1.5
  **chr6:49815874--49815887**      **T**         **intron**   **CRISP1**                             **54**                   **41%**                  **108**                **11%**                **1.5**
  chr8:121518869--121518882        T             intron       MTBP                                   39                       36%                      72                     6%                     1.5
  chr12:22676634--22676648         A             intron       C2CD5                                  52                       40%                      97                     12%                    1.5
  chr10:93579112--93579132         T             intron       TNKS2                                  43                       37%                      103                    8%                     1.5
  chr17:47899281--47899294         A             intron       KAT7          3                        30                       33%                      81                     2%                     1.5
  chr3:50095097--50095118          T             intron       RBM6                                   61                       36%                      76                     8%                     1.4
  chr7:36465607--36465621          T             intron       ANLN                                   90                       44%                      154                    21%                    1.4
  chr19:21558016--21558032         TG            intron       ZNF738                                 159                      48%                      186                    27%                    1.4
  chr12:106500161--106500174       A             intron       NUAK1         1, 2                     53                       32%                      121                    5%                     1.4
  chr17:57078816--57078830         A             intron       TRIM37        1, 4                     33                       27%                      100                    1%                     1.4
  chr1:169555368--169555380        A             intron       F5            1                        82                       28%                      161                    4%                     1.3
  **chr2:203680555--203680567**    **A**         **intron**   **ICA1L**                              **99**                   **24%**                  **177**                **1%**                 **1.3**
  chr4:22444252--22444266          A             intron       GPR125                                 77                       26%                      111                    4%                     1.3
  **chr20:5167156--5167168**       **T**         **intron**   **CDS2**      **2, 5**                 **61**                   **23%**                  **146**                **0%**                 **1.3**
  chr17:66041872--66041885         T             intron       KPNA2         3                        69                       30%                      159                    10%                    1.3
  chr6:76728584--76728597          A             intron       IMPG1                                  68                       24%                      111                    3%                     1.3
  chr10:22515002--22515024         A             intergenic   \-                                     54                       22%                      111                    2%                     1.3
  chr5:86679677--86679690          T             intron       RASA1         4                        67                       21%                      116                    1%                     1.3
  **chr15:89811883--89811895**     **T**         **intron**   **FANCI**                              **47**                   **19%**                  **135**                **1%**                 **1.2**
  chr10:94266331--94266345         T             intron       IDE           2                        82                       18%                      75                     0%                     1.2
  chr18:2960513--2960525           A             intron       LPIN2         1,2,4                    67                       18%                      90                     0%                     1.2
  chr15:64972761--64972788         TG            intron       ZNF609                                 121                      23%                      208                    8%                     1.2
  chr16:10783089--10783101         A             intron       TEKT5                                  66                       17%                      130                    0%                     1.2
  chr4:71888333--71888347          T             intron       DCK           2                        49                       16%                      111                    0%                     1.2
  chr1:236721453--236721465        A             intron       HEATR1                                 101                      17%                      150                    1%                     1.2
  chrX:11187894--11187905          T             intron       ARHGAP6                                61                       16%                      187                    2%                     1.2
  chr11:89534160--89534172         A             intron       TRIM49                                 80                       15%                      131                    1%                     1.2
  chr6:89638989--89639003          A             intron       RNGTT                                  94                       15%                      130                    1%                     1.2
  chr4:141448596--141448609        T             intron       ELMOD2                                 100                      14%                      157                    1%                     1.1
  **chr6:170881390--170881402**    **T**         **3utrE**    **TBP**       **3,5**                  **78**                   **13%**                  **221**                **0%**                 **1.1**
  **chr8:107704941--107704954**    **A**         **intron**   **OXR1**                               **119**                  **13%**                  **188**                **0%**                 **1.1**
  chr7:31132236--31132248          T             intron       ADCYAP1R1     2                        114                      12%                      192                    2%                     1.1
  **chr8:30933817--30933828**      **T**         **intron**   **WRN**                                **132**                  **10%**                  **230**                **0%**                 **1.1**
  **chr7:122757720--122757732**    **A**         **intron**   **SLC13A1**                            **92**                   **9%**                   **183**                **0%**                 **1.1**
  chr19:20829219--20829233         AC            intron       ZNF626                                 203                      5%                       281                    0%                     1.1

Genotyping of microsatellites using methods that dramatically improve the accuracy of microsatellite allele calling \[[@R10]\], allowed us to evaluate microsatellite loci based on the genotype rather than haplotype. Sixty microsatellite loci were identified as significantly differentiating OV from healthy individuals (Table [1](#T1){ref-type="table"}). Of these, only 13 (21.7%) had a modal genotype in the 1kGP that was either heterozygotic with only one of the two prominent alleles represented by the reference allele length or homozygotic and differed from the reference allele length for that microsatellite (Table [1](#T1){ref-type="table"}). This substantiates our comparison based on the modal genotype within a population as being able to identify additional significant differences that may not have been identified using a single microsatellite allele length as a reference.

Three of the sixty informative microsatellite loci were exonic, and an additional locus has been identified in human mRNA (Table [1](#T1){ref-type="table"}). One of the genes, MTMR11 (Entrez gene ID: 10903), is a member of the protein tyrosine phosphatase family, and has been shown to be downregulated in some HER2 breast cancers \[[@R16]\]. Another of the genes, APOA4 (Entrez gene ID: 337), has previously been identified as a potential biomarker for malignant tumor differentiation in OV \[[@R17]\]. The third exonic microsatellite was in the 3′UTR of TATA-binding protein TBP (Entrez gene ID: 6908). TBP and its associated factors (TAFs) make up transcription factor IID and coordinate transcription by RNA polymerase II. The 3′UTR is a common target for regulation by miRNA and therefore microsatellite variation in this region could potentially have effects on protein stability and, in the case of TBP, broader effects on cellular transcription.

Variation of intronic microsatellites has been shown previously to be capable of affecting mRNA splicing and may contribute to disease \[[@R18], [@R19]\]. Of the 60 informative microsatellite loci, 5 are associated with known spliced ESTs (Table [1](#T1){ref-type="table"}). These include a microsatellite associated with KPNA2 (Entrez gene ID: 3838), a protein involved in nuclear transport and a potential regulator of DNA recombination and cell proliferation which has been shown to be upregulated in OV \[[@R20]--[@R22]\], and a microsatellite associated with KAT7 (Entrez gene ID: 11143), a lysine acetyltransferase that may act as a coactivator of TP53-dependent transcription \[[@R23]\].

Our analysis does not attempt to draw direct functional relationships between the OV-associated microsatellite genotypes and altered protein function, but functional annotation enrichment analysis of terms associated with the set of genes containing the 60 OV loci revealed enrichment of rRNA processing/ribosome biogenesis genes (*p* = 0.037). Ribosome biogenesis is a limiting factor that must be overcome in tumorigenesis \[[@R24]\] and therefore individuals with minor alterations in rRNA processing may be at increased risk of cancer.

Risk classifier {#s1_3}
---------------

The presence of predominantly modal or non-modal genotypes at each of the 60 significant loci within the OV germline samples was used to create a 'Cancer Profile' for OV. We assembled a risk classifier based on the fraction of callable loci in each sample (healthy and cancer) for which the genotype matched the Cancer Profile. Based on the ROC curve (Figure [1](#F1){ref-type="fig"}) we determined the threshold for calling a germline genome as 'cancer-like' or having an OV-signature to be 83%. Therefore individuals having the cancer-associated microsatellite genotype at ≥ 84% of the signature microsatellite loci are classified by our method as 'Cancer-like' or potentially having an increased risk of OV. Using this cut-off, we classified the OV germline genomes as at risk for OV with a sensitivity of 90.1% and specificity of 87.6%. Excluding those samples in which less than 10% of the signature loci were genotyped, 264 of the 293 OV germline samples were identified as 'cancer-like' whereas only 26 of the 209 healthy females were flagged as having an increased risk for OV or 'cancer-like' (Figure [2](#F2){ref-type="fig"}). The 1kGP-EUF samples had a mean of 20.1 ± 8.8 of the 60 loci genotyped with 13.1± 7.4 identified as matching the cancer genotype whereas the OV germline samples had a mean of 25.0 ± 9.9 loci genotyped and 22.7 ± 9.0 loci identified as matching the cancer genotype (Table [2](#T2){ref-type="table"}). This confirms that both populations were comparable in the per-exome mean number of loci genotyped, and that the difference lies in the number of loci that match the cancer profile.

![ROC curve using OV germline genotypes at the 60 microsatellite loci which had significantly different genotype distributions between OV and normal genomes](oncotarget-06-11407-g001){#F1}

![Microsatellite variation signature evaluated as a composite of the 60 statistically significant loci\
The non-overlapping distributions (healthy and cancer germline) is illustrative of the power to distinguish those populations. The dashed line marks where the 83% cut-off for calling a sample "OV-like" lies.](oncotarget-06-11407-g002){#F2}

###### The mean numbers of OV and BC signature loci genotyped are within standard deviation for each population

  Population        OV Loci GenotypedMean (SD)   OV "Cancer-like" LociMean (SD) / %   BC Loci GenotypedMean (SD)   BC "Cancer-like" LociMean (SD) / %
  ----------------- ---------------------------- ------------------------------------ ---------------------------- ------------------------------------
  **1kGP-EUF**      20.1 (8.8)                   13.1 (7.4) / 65%                     15.5 (6.4)                   8.9 (3.9) / 57%
  **OV Germline**   25.0 (9.9)                   22.7 (9.0) / 91%                     16.5 (6.5)                   13.4 (5.5) / 81%
  **OV Tumor**      30.2 (6.7)                   26.7 (6.9) / 88%                     NA                           NA
  **BC Germline**   20.5 (7.7)                   6.2 (7.2) / 79%                      17.1 (4.9)                   14.7 (4.3) / 86%

Although our signature loci were identified through comparison of the germline exomes of individuals diagnosed with OV to the control 'healthy' population, we found that when we analyzed the 54 OV tumor samples, 40 (74%) were classified as 'cancer-like' by our method, whereas only 14 (26%) were not identified as 'cancer-like' (Figure [2](#F2){ref-type="fig"}). Twenty-nine of the OV tumors were matched with germline samples. Table [2](#T2){ref-type="table"} shows that of these, both the tumor and germline were identified as 'OV' for 21 individuals (72%). There were an additional 7 individuals (33%) for which only the germline was identified as 'OV' and only one individual (4.8%) whose germline was not identified as 'Cancer-like' while the tumor sample was. There were no individuals for which neither the germline nor the tumor exome was classified as 'Cancer-like' by our method.

Concordance of genotypes between the matched OV samples {#s1_4}
-------------------------------------------------------

We examined the matched germline and tumor samples in greater detail. We are able to genotype a similar number of microsatellites in the matched samples, with a mean of 33966 ± 3008 loci genotyped in the germline samples and a mean of 33881 ± 3621 in the tumor samples. A mean of 30013 ± 3042 loci were genotyped in both samples, and of those an average of 99.6% of those were concordant (had no change in genotype) between the two samples (Table [3](#T3){ref-type="table"}). There was a mean of 135 loci per matched pair for which the genotype was discordant. However, we found that the discordance was primarily due to the tumor being homozygotic at a locus that was genotyped as heterozygotic in the germline (Table [4](#T4){ref-type="table"}). Loss of heterozygosity (LOH) has been associated with OV \[[@R25]\], and the high percentage of discordant loci showing a loss of an allele is consistent with potential LOH.

###### Concordance between genotype calls for those loci that were genotyped in matched tumor and germline samples

  Participant ID (from CGHub)                   Microsatellite loci genotyped in germline samples   Microsatellite loci genotyped in tumor samples   Microsatellite loci genotyped in both samples   Percent of loci whose genotype did not change   Total loci with a genotype change
  --------------------------------------------- --------------------------------------------------- ------------------------------------------------ ----------------------------------------------- ----------------------------------------------- -----------------------------------
  **99f1ae02--86ec-4d93--8cd4--650bf6f02c10**   34520                                               35000                                            31644                                           99.56%                                          140
  **4e6f88de-7624--4719-8234--4c9e5b2e2988**    36203                                               38368                                            32978                                           99.59%                                          134
  **c0c3caab-9277--4a31-a96c-c607e38d5ccc**     37073                                               38394                                            32796                                           99.58%                                          138
  **bc4bc342--20bf-40c3-af26--2c6f942da93d**    34085                                               33010                                            30611                                           99.54%                                          142
  **d7f82e34--5b34--4e8c-a0cf-d7561bcea43c**    33219                                               34426                                            31315                                           99.72%                                          88
  **15170c7f-5880--4fb6--82ce-68d3df0dfb68**    34699                                               32049                                            28937                                           99.55%                                          130
  **1d192835--524e-429d-bf74--3c4727acb446**    26236                                               30068                                            24182                                           99.57%                                          103
  **067c5c61-d147--4b08-ab8a-32c30969d564**     32870                                               32752                                            29467                                           99.59%                                          120
  **fe402983--70da-44db-b7b1-c32702ddde26**     33095                                               34636                                            30829                                           99.55%                                          139
  **25a0a9e6--4f5b-45d8--8f34-abfd31d5ff1b**    28086                                               30409                                            26132                                           99.53%                                          123
  **94bd4c68--4bfc-4db3--9365-97c867747133**    38903                                               35810                                            33186                                           99.44%                                          185
  **538acb2a-c4ca-4656-a91c-841a42dbf15f**      30982                                               30940                                            28150                                           99.59%                                          116
  **9bf16a89--2fc7--4c08--93bc-3105eec5c3cc**   36652                                               35583                                            30508                                           99.50%                                          153
  **f007fa7a-7da9--4cb0--8aea-623af1a122c5**    37568                                               39147                                            33420                                           99.49%                                          172
  **bc3e0b74-ea09--46a5--9f61--16bd15ffd883**   28946                                               38352                                            27525                                           99.30%                                          192
  **44493c23--82e9--4d9f-8e3c-7b3f9ae44970**    31361                                               32433                                            28154                                           99.53%                                          132
  **700e91bb-d675--41b2-bbbd-935767c7b447**     32455                                               31604                                            29193                                           99.62%                                          111
  **8783e4b0--2b62--45d5--8cd9-f5a71cc0138e**   33192                                               33002                                            29848                                           99.63%                                          109
  **d0673efd-3315--4dd5--8ab6--912bfa07dceb**   32512                                               33874                                            29947                                           99.45%                                          166
  **60cce7ac-d27d-44a6--9873-ecf91da5e906**     35536                                               33135                                            30532                                           99.50%                                          153
  **a85f6f9c-1e1d-44fc-85eb-3b2d96cfbc61**      34736                                               34209                                            31701                                           99.56%                                          138
  **66dc6379-a98b-498f-8109-e3a811d043ea**      38597                                               37074                                            33637                                           99.57%                                          144
  **ee0a4a13--613e-4c5d-96c3--8083a013702d**    33755                                               35583                                            31398                                           99.61%                                          122
  **a88b7e66--5f12--4023-a7e2-fcfbd1f25977**    33402                                               30381                                            28370                                           99.51%                                          138
  **cbc5b936-ead5--4858-ab90-e639402789b0**     38030                                               35882                                            33150                                           99.52%                                          158
  **7248cd60-be22--44bc-bc58-f644db0940a2**     36368                                               20670                                            19339                                           99.81%                                          36
  **14c58def-60ee-48e0-a74b-da4eb77ef344**      33007                                               33671                                            30530                                           99.61%                                          119
  **8a6d2ce3-cc57--451b-9b07--8263782aa23f**    33456                                               34118                                            30483                                           99.48%                                          160
  **4d71dd15-cd01--4dae-ad70--6dc325140207**    35475                                               37981                                            32405                                           99.53%                                          151

###### Microsatellite loci whose genotypes between matched tumor and germline samples were discordant predominantly showed loss of an allele

  Participant ID (from CGHub)                   Total Number of discordant loci   Percent of discordant loci with LOH   Percent of discordant loci with an allele gain   Percent of discordant loci with no concordant allele
  --------------------------------------------- --------------------------------- ------------------------------------- ------------------------------------------------ ------------------------------------------------------
  **99f1ae02--86ec-4d93--8cd4--650bf6f02c10**   140                               78%                                   21%                                              1%
  **4e6f88de-7624--4719-8234--4c9e5b2e2988**    134                               72%                                   25%                                              2%
  **c0c3caab-9277--4a31-a96c-c607e38d5ccc**     138                               65%                                   28%                                              7%
  **bc4bc342--20bf-40c3-af26--2c6f942da93d**    142                               80%                                   15%                                              4%
  **d7f82e34--5b34--4e8c-a0cf-d7561bcea43c**    88                                39%                                   60%                                              1%
  **15170c7f-5880--4fb6--82ce-68d3df0dfb68**    130                               75%                                   19%                                              5%
  **1d192835--524e-429d-bf74--3c4727acb446**    103                               79%                                   17%                                              5%
  **067c5c61-d147--4b08-ab8a-32c30969d564**     120                               69%                                   28%                                              3%
  **fe402983--70da-44db-b7b1-c32702ddde26**     139                               64%                                   30%                                              6%
  **25a0a9e6--4f5b-45d8--8f34-abfd31d5ff1b**    123                               66%                                   32%                                              2%
  **94bd4c68--4bfc-4db3--9365-97c867747133**    185                               71%                                   28%                                              1%
  **538acb2a-c4ca-4656-a91c-841a42dbf15f**      116                               72%                                   27%                                              1%
  **9bf16a89--2fc7--4c08--93bc-3105eec5c3cc**   153                               69%                                   29%                                              3%
  **f007fa7a-7da9--4cb0--8aea-623af1a122c5**    172                               71%                                   27%                                              2%
  **bc3e0b74-ea09--46a5--9f61--16bd15ffd883**   192                               82%                                   13%                                              6%
  **44493c23--82e9--4d9f-8e3c-7b3f9ae44970**    132                               70%                                   27%                                              3%
  **700e91bb-d675--41b2-bbbd-935767c7b447**     111                               66%                                   32%                                              2%
  **8783e4b0--2b62--45d5--8cd9-f5a71cc0138e**   109                               73%                                   22%                                              5%
  **d0673efd-3315--4dd5--8ab6--912bfa07dceb**   166                               73%                                   23%                                              4%
  **60cce7ac-d27d-44a6--9873-ecf91da5e906**     153                               73%                                   25%                                              3%
  **a85f6f9c-1e1d-44fc-85eb-3b2d96cfbc61**      138                               67%                                   29%                                              4%
  **66dc6379-a98b-498f-8109-e3a811d043ea**      144                               69%                                   28%                                              3%
  **ee0a4a13--613e-4c5d-96c3--8083a013702d**    122                               67%                                   30%                                              2%
  **a88b7e66--5f12--4023-a7e2-fcfbd1f25977**    138                               81%                                   16%                                              3%
  **cbc5b936-ead5--4858-ab90-e639402789b0**     158                               72%                                   25%                                              3%
  **7248cd60-be22--44bc-bc58-f644db0940a2**     36                                83%                                   14%                                              3%
  **14c58def-60ee-48e0-a74b-da4eb77ef344**      119                               80%                                   19%                                              1%
  **8a6d2ce3-cc57--451b-9b07--8263782aa23f**    160                               83%                                   15%                                              3%
  **4d71dd15-cd01--4dae-ad70--6dc325140207**    151                               64%                                   32%                                              4%

Cross-analysis with BC {#s1_5}
----------------------

The link between OV and breast cancer (BC) is well documented \[[@R26]\], however most of the studies have focused on hereditary BC/OV which can be attributed to BRCA1/2 \[[@R27]\]. There may also be some overlap in risk between non-hereditary BC and OV. We examined the overlap in the loci identified in this study as markers for OV risk and those identified in a similar study of BC individuals \[[@R14]\]. Fifteen of the 60 OV-associated loci were also identified as significant between BC and healthy individuals (demarked with blue, Table [1](#T1){ref-type="table"}). We analyzed 647 BC germline samples obtained from TCGA using the OV profile and found that 193 (30%) of the BC individuals fall above the 83% cut-off of loci match the OV profile and were therefore classified by our method as 'cancer-like' for OV (Figure [3A](#F3){ref-type="fig"}). The overlap seen here in both the 15 loci that were included in both cancer-signature sets and the individuals that were classified has 'cancer-like' for both the signatures suggests that the link between BC and OV carries through in our method. In the reciprocal study, we analyzed each of the OV germlines at the published BC loci \[[@R14]\] and found that 181 (70%) of the 259 OV individuals were also classified as 'cancer-like' for BC as compared to 564 (87%) of BC individuals classified as 'cancer-like' using the BC signature (Figure [3B](#F3){ref-type="fig"}). Of the 259 OV exomes that could be evaluated by both signatures, 166 (64.1%) were classified as 'cancer-like' using both the BC and OV signature loci sets while 66 (25.5%) were classified as 'cancer-like' by just the OV signature set and 15 (6.8%) by just the BC set. Only twelve individuals were not classified as 'cancer-like' using either signature. Conversely, of the 190 1kGP-EUF exomes that were evaluated by both signatures, 11 (5.8%) were identified as cancer-like by both signatures whereas 135 (71%) were not identified as cancer-like by either signature.

![Cross analysis of the OV and BC samples and significant loci sets\
**(A)** Evaluation of the 1kGP-EUF healthy control, OV and BC germline exomes using the OV-signature set of microsatellites. **(B)** Evaluation of the 1kGP-EUF healthy control, OV and BC germline exomes at the BC-signature set of microsatellites.](oncotarget-06-11407-g003){#F3}

DISCUSSION {#s2}
==========

Currently there are few biomarkers for early detection of OV, and our evaluation of an OV-signature of microsatellite variation could prove to be a valuable additional resource for identifying those individuals who would benefit from increased surveillance for OV. Our analysis of microsatellites from OV genomes from TCGA is unique in that it not only assesses genomic microsatellite variations that arise in tumors, which are well known to be unstable, but it can identify low, but significant, levels of genomic microsatellite variation within the germline compared to the general population. We were able to identify a distinct subset of 60 microsatellite loci associated with OV, each of which has power to differentiate the germlines of healthy females from those that have developed ovarian cancer. Individually, these also inform as to possible mechanism and are potential new therapeutic targets, but together as a set, they could be used to identify genomes that carry an 'OV risk signature'. The most significant finding is that we were able to identify the OV signature in the germline of OV patients, not the tumor, therefore, variation at these loci has potential use as a risk-assessment screening method and may be included along with other analyses in informing a physician\'s decision on patient care and monitoring of an individual. The specificity of this assay is too low to be used as a general population screen, so would be most appropriately applied to the subset of women who have a family history of breast or ovarian cancer or other risk factors such as unexplained infertility \[[@R28], [@R29]\]. In addition to analyzing OV germline exomes at the 60 signature loci, we were able to perform a cross-analysis of OV and BC using the OV loci found here and 55 loci that were previously published as differentiating BC from normal. Fifteen loci were joint loci, i.e. were identified in both risk sets including in genes that have roles in DNA repair (e.g. WRN and FANCI) or roles in transcription regulation (TBP). The overlap in informative loci found in both OV and BC may represent those loci that increase broad-spectrum cancer risk. In addition, we were able to identify 30% of breast cancer exomes as 'at risk' for OV whereas 70% of OV were classified as 'at risk' for BC. This may indicate enhanced susceptibility to a second primary tumor development in these patients. As more genomic data becomes available it will be critical to validate these observations, and determine how these variants imply mechanism, as part of translating these findings into clinical utility.

METHODS {#s3}
=======

Data sets {#s3_1}
---------

A set of 249 exomes from healthy European females was used as the control group to establish the expected microsatellite genotypes. These individuals were exome sequenced at high coverage by the 1000 Genomes Project \[[@R30]\]. These were compared to exome sequencing data from 305 germline samples from individuals with ovarian cancer (OV) and 54 tumor samples (29 of which were matched), which were sequenced by The Cancer Genome Atlas for study phs000178.v5.p5 \[[@R6]\]. Because of the documented assembly inaccuracies at microsatellite loci for all the data emerging from all nextgen sequencing projects, we did not use the assemblies provided to make microsatellite genotype calls, instead each microsatellite was re-built using the raw data and our verified algorithms \[[@R11]\]. The raw sequencing reads obtained for this study through NCBI SRA were downloaded, decrypted, and decompressed using software by NCBI SRA. Then they were filtered based on the quality score requirements set forth by the 1000 Genomes Project \[[@R30]\].

Microsatellite-based genotyping {#s3_2}
-------------------------------

Quality filtered reads from The Cancer Genome Atlas \[[@R6]\], were aligned to the human reference genome (NCBI36/hg18) using BWA \[[@R31]\]. Our microsatellite-based genotyping uses non-repetitive flanking sequences to ensure reliable mapping and alignment at microsatellite loci by filtering out all microsatellite-containing reads that do not completely span the repeat as well as provide additional unique flanking sequence on both sides \[[@R10]\]. We then use the unique flanking sequence along with a small portion of the repeat for local alignment of the read to the correct genomic locus. We perform this same procedure on those reads that were not aligned to the reference by BWA, obtaining additional coverage at some loci. Only loci with a coverage of at least 15x in a given sample (healthy or cancer genomes) are considered "callable" and genotyped. See supplemental methods for additional details.

Modal genotype determination {#s3_3}
----------------------------

We compiled the genotypes from all the 1kGP-EUF samples for each microsatellite locus. The genotype supported by the highest number of samples was determined to be the modal genotype. In cases where more than one genotype was equally represented, the genotype listed first in our compiled set was used consistently as the modal genotype.

Computing statistics for each microsatellite locus {#s3_4}
--------------------------------------------------

2 × 2 tables were created for each locus for the 1kGP-F normals and the OV germline samples that were called in at least 10 samples in each set: 1kGP-EUF with modal/non-modal genotypes by OV germline with modal/non-modal genotypes. An R script computed the *p*-value for each locus using the two sided fisher.test function. The Benjamini-Hochberg cut-off was selected as 0.01% (FDR \< 1/3750 (total number of loci with *p*-value \< 1)) to make it unlikely that any locus is a false positive from our data set. 60 loci passed the FDR and were considered to be informative in distinguishing the healthy EUF from the cancer samples. Relative risk for each locus was computed as the percent of individuals with the non-modal genotype from the cancer set divided by the percent of individuals with the non-modal genotype in the normal set.

ENCODE, etc {#s3_5}
-----------

ENCODE and related data for the 60 informative microsatellite loci was obtained from the UCSC Genome Browser \[[@R32], [@R33]\].

Calculating the risk classifier {#s3_6}
-------------------------------

Using the 60 loci that significantly differentiated OV genomes from healthy genomes, we plotted an ROC curve for the sensitivity and specificity spectrum and identified the point of inflection as the cut off for identifying an exome as 'cancer-like'. We then evaluated each exome at the 60 informative OV loci. Any individual exome in which fewer than 10% of the informative loci was genotyped was not included in the subsequent analyses.

Ontology {#s3_7}
--------

GO enrichment analysis of genes associated with the 60 signature loci was performed using DAVID \[[@R34], [@R35]\] functional annotation tools (*p* \< 0.1), Genedecks \[[@R36]\] and GSEA \[[@R37]\]. Pathway enrichment was performed using Panther \[[@R38]\].
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